Blood Cancer J April 2023 PMID 37095094

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies.

Yinqiang Zhang, Chenggong Li, Mengyi Du, Huiwen Jiang, Wenjing Luo, Lu Tang, Yun Kang, Jia Xu, Zhuolin Wu, Xindi Wang, Zhongpei Huang, Yanlei Zhang, Di Wu, Alex H Chang, Yu Hu

Download social card

Mentions

Peak: 10 in Apr 2023

across 3 sources since Apr 2023

Extended reach

26,326

potential audience

Total likes

Video views

Mentions per month

Apr 2023 – Aug 2023

Where it's discussed

X / Twitter10 posts
News2 articles
YouTube1 videos

AI synopsis

What people are saying

The discussions consistently refer to the therapeutic promise of allogeneic and autologous anti-CD7 CAR-T cell therapies, with some posts including their specific contexts like lymphoma, which highlights their clinical relevance. The tone is generally positive and supportive, using words like 'potential' and hashtags like '#lymsm' and '#leusm' to underscore interest and perceived impact in the medical community.

AgreementModerate agreement

Most discussions recognize the potential of allogeneic CAR-T therapies for T-cell malignancies, indicating support for the article's findings.

InterestModerate interest

The mentions of specific contexts like lymphoma and leukemia suggest a moderate level of curiosity among participants.

EngagementModerate engagement

Posts include hashtags and brief references, showing engagement but limited in-depth analysis.

ImpactModerate impact

The repeated emphasis on the clinical potential hints at a recognition of meaningful progress in cancer treatment research.

Abstract in brief

This study explores the use of allogenic and autologous anti-CD7 CAR T-cell therapies in treating relapsed or refractory T-cell malignancies, specifically T-cell acute lymphoblastic leukemia (ALL) and lymphoma, highlighting that allogeneic CART cells may offer higher remission rates and more durable responses than autologous cells.
The research involved a phase I trial with 10 patients, showing that there were no severe toxicity issues like doselimiting toxicity or neurotoxicity; common side effects included cytokine release syndrome, but most patients achieved complete remission with minimal residual disease negativity within one month.
The findings suggest that allogeneic CART cells could be a more effective and promising treatment option for T-cell malignancies, given their higher remission and lower recurrence rates, emphasizing the need for further investigations into this therapy.]

Read the full abstract

All mentions

Allogenic vs Autologous Anti-CD7 CAR-T Cell Therapies for T-cell Malignancies

This study explores allogenic and autologous anti-CD7 CAR T-cell therapies in relapsed or refractory T-cell malignancies, highlighting higher remission rates with allogeneic CAR-T cells and minimal severe toxicity in a…

Social RTCL TV · Aug 4, 2023 8 views

Dr. Avinash Dinmohamed

@ADinmohamed · X